The p14 ARF , p15 INK4B , and p16 INK4A genes are important negative cell-cycle regulators often inactivated by deletions, mutations, or hypermethylation in malignancy. Hypermethylation of the three genes was studied in 81 patients with therapyrelated myelodysplasia (t-MDS) or acute myeloid leukemia (t-AML) by methylation-specific PCR, and p15 methylation additionally by bisulfite genomic sequencing. In all, 55 patients disclosed p15 methylation, five patients showed p16 methylation, whereas p14 methylation was not observed. Methylation of p15 was closely associated with deletion or loss of chromosome arm 7q (P ¼ 0.0006). In t-MDS, the p15 methylation frequency and the p15 methylation density both increased significantly by stage (P ¼ 0.004 and 0.0002), and p15 methylation frequency increased with an increasing percentage of myeloblasts in the bone marrow (P ¼ 0.006). In a two-variable Cox model including the percentage of myeloblasts, p15 methylation was an independent prognostic factor (P ¼ 0.005). Methylation of p15 was less common in t-AML of subtype M5 than in other FAB subtypes (P ¼ 0.03). Methylation of p15 was unrelated to type of previous therapy, to latent period from start of therapy, to platelet count, and to p53 mutations. Inactivation of p15 and deletion of genes on chromosome arm 7q possibly cooperate in leukemogenesis.
Introduction
A complicated network of genes organized in the p53 pathway or the retinoblastoma (Rb) pathway regulates progression from the G1 to the S phase of the cell cycle. One or both pathways are disrupted in most human cancers leading to cell-cycle deregulation, uncontrolled cell proliferation, and malignant transformation. [1] [2] [3] The p14 ARF (p14), p15 INK4B (p15), and p16 INK4A (p16) genes, located within a small 25 kb fragment on chromosome band 9p21, are as negative cell-cycle regulators putative tumor suppressor genes. The p14 protein binds to and inhibits Mdm2-dependent degradation of the p53 protein in the p53 pathway, whereas the cyclin-dependent kinase (CDK) inhibitors p15 and p16 directly binds and negatively regulates CDK4-and CDK6-mediated phosphorylation and inactivation of the Rb protein in the Rb pathway. [1] [2] [3] The p15 gene is an effector of antimitotic signaling by the transforming growth factor-b (TGF-b), 4 which has been shown to be a multifunctional regulator of normal hematopoiesis. 5 Restricted to the myeloid lineage of cells, p15 expression is undetectable in CD34 + progenitor cells, but strongly upregulated by autocrine production of TGF-b during terminal differentiation of granulocytes. [6] [7] [8] [9] [10] The p16 gene, on the other hand, is highly expressed in CD34 + progenitor cells, but downregulated during terminal myeloid differentiation. 9 Inactivation of the p14, p15, or p16 genes by homozygous deletion, point mutation or by hypermethylation of the CpG sites at the promoter region has been observed in different neoplasias. Whereas point mutations are very rare in hematopoietic malignancies, disruption of the three genes by homozygous deletion, or silencing of p15 and p16 by promoter hypermethylation, are common in lymphoid malignancies as acute lymphoblastic leukemias and multiple myeloma. 11 In myeloid malignancies as de novo myelodysplasia (MDS) and acute myeloid leukemia (AML), p15 but not p16 is frequently silenced by aberrant promoter methylation, [12] [13] [14] [15] whereas deletions are uncommon. 11 In MDS, p15 methylation was associated with a high percentage of myeloblasts in the bone marrow, with transformation to AML, and in univariate analysis predicted a poor prognosis. 13, 14, 16 Therapy-related MDS (t-MDS) and AML (t-AML) are of particular interest, as most cases are directly induced by treatment with alkylating agents or with topoisomerase II inhibitors, 17 resulting in different cytogenetic and genetic characteristics of the diseases. 18 At least eight genetic pathways of t-MDS and t-AML were recently outlined. 19 The purpose of the present study was to examine the methylation status of the p14, p15, and p16 gene promoters in 81 unselected patients with t-MDS or t-AML and to relate the results to type of previous therapy, to clinical, cytologic, and cytogenetic characteristics, as well as to the different genetic pathways of the disease.
Methylation of p14, p15, and p16 was first studied by the very sensitive methylation-specific PCR (MSP). 20 As by this method only p15 was shown to be methylated in a considerable percentage of the patients, the methylation status of p15 was subsequently studied by the alternative, more laborious direct bisulfite genomic sequencing (BGS). 21, 22 Whereas the MSP method can detect methylation of only a few CpG sites, the less sensitive BGS method identifies the methylation status of every CpG site within a PCR-amplified sequence allowing a quantitative estimation of the methylation density. 21, 22 This is important because previous studies have shown that the methylation pattern of the p15 gene is heterogeneous, 15, 23 and that the methylation density is a critical factor for transcriptional silencing of the p15 gene in AML. 23 Patients, materials and methods
Patient and control samples
Bone marrow mononuclear cells, or in a few cases blasts from peripheral blood, of 50 unselected patients presenting with t-MDS and 31 unselected patients presenting with t-AML were studied at diagnosis of the disease. Cells from 75 of these patients had previously been examined for p53 mutations 24 and another six new unreported cases of t-MDS or t-AML were included. Material was no longer available from previously reported cases nos. 110 and 170. A previous study using methylation-sensitive restriction endonucleases and PCR has demonstrated p15 methylation of bone marrow cells from patients treated intensively for malignant lymphomas without having developed t-MDS or t-AML. 25 We therefore examined bone marrow cells from 13 patients in complete remission following intensive therapy of Hodgkin's disease for p15 methylation. These patients were without clinical signs or symptoms of t-MDS or t-AML, had normal blood cell counts, normal bone marrow cytology and normal cytogenetics.
Sodium bisulfite conversion of genomic DNA
Treatment with sodium bisulfite efficiently converts unmethylated cytosine residues to uracil, whereas 5-methylcytosine residues remains unchanged. This change of sequence of DNA reflects the methylation status at CpG dinucleotides in the genomic DNA, and is the basis of the MSP and BGS techniques used (see below).
Sodium bisulfite conversion of genomic DNA was carried out essentially as previously described. 26 Genomic DNA was first extracted from cryopreserved cells with the TRIzol reagent (GIBCO Life Technologies, Grand Island, NY, USA). Approximately, 1 mg of DNA was then denatured in 30 ml of 0.5 M NaOH at 371C for 15 min. Subsequently, 450 ml of a mixture of 4.5 M sodium bisulfite (Sigma, Vallensbaek Strand, Denmark) and of 0.6 M hydroquinone (Sigma) (pH 5.0) was added. The mixture was incubated under mineral oil at 551C for 4-8 h. The bisulfitetreated DNA was purified with Wizard DNA Clean-up System (Promega, Madison, WI, USA) and eluted into 50 ml of dH 2 O. Incubating the DNA in 0.3 M NaOH at 371C for 15 min completed desulfonation. Finally, the bisulfite-converted DNA was recovered using the QIAEX II kit (Qiagen) and dissolved in 50 ml elution buffer (10 mM Tris-HCl, pH 8.0). As methylated control for the three genes was used universally, methylated DNA (Intergen, Oxford, UK), and in addition DNA from the KG-1a and the Raji cell lines, was used as methylated controls for the p15 and p16 gene promoters. DNA isolated from peripheral blood of six normal individuals was used as unmethylated control.
Methylation-specific PCR
A two-step PCR method was applied for analyzing the methylation status of p15, because this method has been shown to improve the sensitivity and the specificity of a single-step MSP. 27 In the first-step, modification-specific primers (p15mod-1F and p15mod-1R) were designed to selectively amplify fully sodium bisulfite-converted DNA without discriminating between methylated or unmethylated p15 (Table 1) . 22 A volume of 2 ml of sodium-bisulfite-converted genomic DNA was included in the initial PCR. This PCR was diluted 50-fold and 1 ml was used as template in the second-step MSP as well as in secondstep BGS (see below). In the second-step MSP, methylationspecific primers (M) and unmethylation-specific primers (UM) ( Table 1) were designed to selectively amplify methylated and unmethylated p15. 20 Two different primer sets were used to selectively amplify methylated p15: primer set 1 with two methylation-specific primers (p15M-1F/p15M-1R), 20 and primer set 2 with one indiscriminate primer (p15mod-2F) and one methylation-specific primer (p15M-1R) ( Table 1 , Figure 1 ). PCR was performed in 20 ml including 1 Â PCR buffer (Qiagen), 1 Â Qsolution (Qiagen), 0.1 mM dNTP (Pharmacia Biotech), 0.4 mM of each primer (DNA Technology), 1 U HotStarTaq polymerase (Qiagen). Temperature profiles for first-step PCR were as follows: initial denaturation at 951C for 15 min, followed by 40 cycles of 941C for 30 s, 501C for 30 s, 721C for 60 s; and a final extension at 721C for 5 min. Second-step MSP was as described above except for 25 cycles of amplification and an annealing temperature of 641C for primer sets 1 and 2, and of 601C for the unmethylationspecific primers. In a dilution experiment, the two-step MSP method was shown to have a relative detection limit of approximately 1% (ie one out of 1000 cells with p15 methylation, data not shown). To confirm a positive result of MSP, selected cases were subjected to direct sequencing. The methylation status of the p14 and p16 genes were examined by a single-step MSP including 1 ml of sodiumbisulfite-converted DNA and either the methylation-specific primers (p14M-1F/p14M-1R or p16M-1F/p16M-1R) or the unmethylation-specific primers (p14UM-1F/p14UM-1R or p16UM-1F/p16UM-1R) ( Table 1 ). The MSP reaction and amplification condition were as described above except for 45 cycles of amplification and an annealing temperature of 601C.
Direct bisulfite genomic sequencing
Direct sequencing of sodium-bisulfite-converted DNA was performed as a two-step PCR in the second-step, including 1 ml of 50-fold dilution of the first-step PCR (see above) and Table 1 Primers used to analyze the methylation status of the p14, p15, and p16 genes by MSP and BGS
Primer name
Primer sequence 3 0 -5
M, methylation-specific primers; UM, unmethylation-specific primers; mod, modification-specific primers. the nested modification-specific primer pairs p15mod-2F and p15mod-2R (Table 1, Figure 1 ). The PCR reaction and the temperature profiles for second-step PCR was as for first-step PCR (see above) except for the use of 35 cycles of amplification. This assay generates a fragment of 247 bp of the p15 gene promoter encompassing 27 CpG sites located between nucleotide À41 and 206 relative to the transcription start. The secondstep PCR was purified with the JETquick PCR purification kit (Genomed GmbH, Bad Oeynhausen, Germany), and subjected to direct sequencing with the p15mod-2F and p15mod-2R primers using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystem, Foster City, CA, USA). Analyses were performed on a 310 ABI Prism automatic sequencer (Applied Biosystem). Each sample was sequenced at least in duplicate. The p15 methylation density of each sample was calculated as the number of methylated CpG sites divided by the total number of CpG sites sequenced per sample. As a methylation density of less than 10% has been shown to be the threshold for transcriptional silencing of the p15 gene, 23 patients with a methylation density of less than 10% and who also were negative by MSP were considered as unmethylated. A methylation density of 40% or higher was based on the previous study 23 considered to represent complete silencing of the p15 gene.
Results

Methylation status of the p14, p15, and p16 gene promoters
The methylation status of the p15 gene promoter was first examined by the two-step MSP and p15 methylation was observed in 50 of 81 patients (Figure 2a) . Subsequently, the BGS method disclosed a methylation density of more than 10% in 49 of 81 patients, indicating p15 methylation of biological importance (Figure 2b) .
Combining the results of BGS and MSP, a total of 55 of 81 patients (68%) with t-MDS or t-AML disclosed p15 methylation, whereas the remaining 26 patients and the 13 intensively treated controls showed unmethylated p15 ( Table 2 ). A total of 44 patients showed p15 methylation by both methods, five patients were positive by BGS only, and six patients were positive by MSP only (ie methylation level below the detection limit of BGS ( Table 2) . Sequencing of all six cases positive only by MSP confirmed methylation of the CpG sites between the primer binding sites (data not shown). Four of the five patients positive only by BGS showed partial methylation of CpG sites outside the methylationspecific primer binding sites explaining the negative results of MSP.
By MSP five of the 81 patients showed p16 methylation (cases 73, 108, 115, 159, and P), whereas p14 methylation was not observed in any patient.
Methylation of p15 related to FAB subtypes of t-MDS and t-AML
Combining the results of BGS and MSP, the p15 methylation frequency was higher in patients with the advanced stages RAEB/RAEB-t as compared to patients with the early stages RA/ RARS (P ¼ 0.004, Table 3 ). This association was confirmed by relating the p15 methylation status to the actual percentage of myeloblasts in the bone marrow ranging from 0 to 23% (P ¼ 0.006, Wilcoxon's two-sample test).
Also, the p15 methylation density was higher in patients with RAEB/RAEB-t as compared to patients with RA/RARS (P ¼ 0.0002, Wilcoxon's two-sample test), and a methylation density X40% representing complete transcriptional silencing was observed in all 19 methylated cases of overt t-AML (P ¼ 0.05, test for trend) (Figure 3) .
In patients presenting with acute monocytic leukemia (M5), the p15 methylation frequency was lower (20%) than in cases presenting as overt AML of FAB subtypes M0-M3 (80%) Examples of MSP and of BGS analysis of the p15 gene promoter CpG island. (a) Representative results of MSP in five patients (lanes 2-6) and controls (lanes 7-11) amplified with methylationspecific primers (p15M) and unmethylation-specific primers (p15UM). The presence of visible PCR product amplified with p15M or p15UM primers in lanes 2, 3, and 6, indicates the presence of a mixture of methylated and unmethylated p15 in the bone marrow cells from these patients. Bisulfite-converted DNA from normal blood was used as unmethylated control (lane 8), bisulfite-converted DNA from the KG1a cell line and in vitro methylated DNA were used as methylated controls (lanes 9 and 10), and water was used as negative PCR control (lane 11). (b) Three representative DNA sequences of BGS are shown including CpG sites 5-14 of Figure 1 . The wild-type sequence is outlined at the top of the figure. The first DNA sequence shows a case in which all cytosines are converted to thymidines (red) except the methylated cytosines (blue), indicating a methylation density of 100%. The second DNA sequence shows a case in which all cytosines are converted to thymidines indicating a methylation density of 0%. The third DNA sequence shows a case in which all cytosines are converted to thymidines except the methylated cytosines at the CpG sites nos. 5-9 and 14, indicating partial methylation (ie methylation density o100%). The mixture of cytosines and thymidines at CpG site nos. 5-9 and 14, indicates a mixture of methylated and unmethylated p15.
(P ¼ 0.03, Table 3 ). The 11 cases of acute myelomonocytic leukemia (M4) showed an intermediate p15 methylation frequency of 55%.
Methylation of p15 related to clinical characteristics
Methylation of p15 was unrelated to patient age, to gender and to type of previous therapy with alkylating agents, topoisomerase II inhibitors or radiotherapy (Table 4) . Likewise p15 methylation was unrelated to the latent period from start of therapy for the primary malignancy to development of t-MDS or t-AML and to the platelet count (Table 4) . Patients with p15 methylation presented a significantly shorter survival than patients with unmethylated p15 (P ¼ 0.002, Figure 4a ). This difference mainly relates to differences in survival within the group of 50 patients with t-MDS (P ¼ 0.003, Figure 4b ), as the survival of the 31 patients presenting as overt t-AML was in general very short independent of the p15 methylation status (P ¼ 0.18, Figure 4c , all log-rank test).
As an increasing percentage of blasts was also associated with a shorter survival among patients with t-MDS (P ¼ 0.002) in univariate analysis, p15 methylation and percentage of blasts were included in a two-variable Cox model. In this analysis, p15 methylation remained an independent prognostic factor (P ¼ 0.005).
Methylation of p15 related to chromosome aberrations and to specific genetic abnormalities
The most significant observation in the present study was a close association between p15 methylation and a deletion or loss of chromosome arm 7q, the most common cytogenetic abnormalities in t-MDS and t-AML (P ¼ 0.0006, Table 4 ). On the other hand, there was no association between p15 methylation and deletion or loss of 5q or 17p, the second and third most frequent cytogenetic abnormalities in t-MDS and t-AML, or with the presence of one of the recurrent balanced chromosome aberrations (Table 4) . Patients with a complex karyotype and three or more chromosome aberrations showed a somewhat higher p15 methylation frequency as compared to patients with a normal karyotype or one or two chromosome aberrations (P ¼ 0.03, Table 4 ). Interestingly, all five patients with internal tandem duplications of the FLT3 or MLL genes 28 disclosed p15 methylation, whereas there was no association to the presence of p53 mutations. 24 
Discussion
Methylation of the p15 gene promoter was in the present study demonstrated as a frequent epigenetic abnormality in patients Table 2 Methylation of p15 as determined by BGS and MSP in t-MDS and t-AML and treated controls Figure 3 p15 methylation density of 81 patients with t-MDS or with t-AML related to FAB subtypes. An MD of 10% or less represents unmethylated p15, an MD of 40% or higher represents complete transcriptional silencing of the p15 gene. 23 
Table 4
Methylation of p15 related to clinical, cytogenetic and genetic characteristics of 81 patients with t-MDS or t-AML i i with t-MDS or t-AML in-line with previous observations in de novo MDS and AML. [12] [13] [14] [15] [16] Combining the results of the BGS method with the more sensitive MSP method, p15 methylation was observed in 55 of 81 (68%) unselected patients with t-MDS and t-AML, whereas 13 intensively treated controls were all unmethylated. Methylation of p15 was for the first time shown to be highly significantly associated with deletion or loss of chromosome arm 7q. As previously observed in de novo MDS, 13, 14 p15 methylation in t-MDS increased with an increasing percentage of myeloblasts in the bone marrow and predicted a poor prognosis.
Deletions or loss of a whole chromosome arm 7q are the most frequent cytogenetic abnormalities in t-MDS and t-AML observed in 40-50% of the patients. 18 The abnormalities of chromosome 7 have been significantly associated with presentation of the disease as t-MDS and considered as early events in leukemogenesis. Thus, they are observed already at the first clinical signs of the disease and closely related to previous therapy with alkylating agents. 17, 18 Despite much research the critical molecular changes of these deletions has not been clarified. Mutated recessive genes on the remaining normal chromosome 7 have been searched for, so far without success, for which reason haploinsufficiency has been considered. The highly significant association between deletion or loss of 7q and p15 methylation suggests that the two abnormalities cooperate in leukemogenesis. Alternatively, the defects of chromosome 7 could in some way lead to methylation of the p15 gene.
Recently, we proposed different genetic pathways in t-MDS and t-AML. 19 The two most common pathways in patients treated with alkylating agents were pathway I characterized by deletion or loss of 7q but with normal chromosomes 5, and pathway II characterized by deletion or loss of 5q with or without normal chromosomes 7. Pathway II was significantly associated with deletion or loss of chromosome arm 17p and mutation of the p53 gene, with duplication or amplification of chromosome band 11q23 and with a complex karyotype. 24, 29 The present study now outlines p15 methylation as a new and common epigenetic abnormality in t-MDS and t-AML significantly associated with deletion or loss of 7q preferentially observed in pathway I. The distinction between these two pathways was recently supported by a study of gene expression profiles of CD34 + bone marrow cells of patients with t-AML. 30 Distinctive and different expression profiles were observed in patients belonging to pathways I and II, and the results of the present study further underlines the relevance of the model.
Methylation of p15 showed significant associations to FAB subtypes of t-MDS as well as of t-AML. In t-MDS, the p15 methylation frequency and density increased with an advancing stage of the disease and with an increasing percentage of myeloblasts in the bone marrow. These results confirm previous findings in de novo MDS. 13, 14, 16 In cases with overt t-AML, p15 methylation was most common in overt leukemias of the granulocytic types (M0-M3) (80%), less common in acute myelomonocytic leukemia (M4) (55%) and rather rare in acute monocytic leukemia (M5) (20%). The same tendency has been observed in some previous studies of de novo AML, 15, 31 although not confirmed by other studies. 32, 33 The different results may reflect the rather small number of patients with each FAB subtype included in each study. If the results of the five previous studies of de novo AML 15, [31] [32] [33] [34] and the present study of t-AML are combined, the p15 methylation frequency is significantly lower in the M5 subtype of AML as compared to the M0-M3 subtypes (14 of 31 vs 114 of 150, P ¼ 0.001, w 2 test with Yates correlation). This is of interest in relation to the suggested role of p15 in normal granulocytic differentiation. 7, 8 The fact that p15 methylation was more common in cases of RAEB/RAEB-t than in cases presenting as overt t-AML possibly relates to a significant overweight of cases with deletion or loss of chromosome arm 7q in RAEB/RAEB-t, combined with the lower frequency of p15 methylation in overt myelomonocytic or monocytic t-AML. 
Figure 4
Survival (Kaplan-Meier curves) according to p15 methylation status of (a) 81 patients with t-MDS or t-AML, (b) 50 patients with t-MDS, and (c) 31 patients with overt t-AML.
In de novo MDS and AML, p15 methylation has not been demonstrated as an independent prognostic factor, if other parameters as the percentage of myeloblasts in the bone marrow are taken into consideration. 14, 16, 33, 34 In the present study of patients with t-MDS, p15 methylation and the percentage of myeloblasts in the bone marrow were both significant prognostic factors in univariate analyses. Interestingly, in a twovariable Cox model, including the percentage of myeloblasts, the p15 methylation status remained an independent prognostic factor.
Several observations now strongly support that epigenetic inactivation of p15 plays an important role in leukemogenesis. First, p15 has been specifically involved in normal granulocytic differentiation, 7, 8 which is disrupted in MDS and AML. Second, the pronounced p15 methylation observed in the myeloid disorders has been located strictly to the malignant clone of cells, unrelated to their different stage of differentiation. 35 Third, demethylating therapy of patients with MDS with decitabine has been shown to reduce p15 methylation and restore expression of the p15 protein in clinically responding patients. 36 Fourth, p15 methylation seems to be a specific event, since the p14 and p16 genes, located within the same 25 kb fragment of chromosome band 9p21 as the p15 gene, were rarely or never methylated in t-MDS and t-AML. The close association between p15 methylation and deletion or loss of 7q, the associations to specific FAB subtypes of t-MDS and t-AML and the prognostic value, observed in the present study, are all in agreement with an important role of p15 methylation in leukemogenesis.
